CoChat

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Open access
Chen, Liying, Alexe, Gabriela, Dharia, Neekesh V., Ross, Linda, Iniguez, Amanda Balboni, Conway, Amy Saur, Wang, Emily Jue, Veschi, Veronica, Lam, Norris, Qi, Jun, Gustafson, W. Clay, Nasholm, Nicole, Vazquez, Francisca, Weir, Barbara A., Cowley, Glenn S., Ali, Levi D., Pantel, Sasha, Jiang, Guozhi, Harrington, William F., Lee, Yenarae, Goodale, Amy, Lubonja, Rakela, Krill-Burger, John M., Meyers, Robin M., Tsherniak, Aviad, Root, David E., Bradner, James E., Golub, Todd R., Roberts, Charles W.M., Hahn, William C., Weiss, William A., Thiele, Carol J., Stegmaier, Kimberly · 2017 · Journal of Clinical Investigation
Cited by 152

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma and found a preferential dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12. Genetic and pharmacological suppression of EZH2 inhibited neuroblastoma growth in vitro and in vivo. Moreover, compared with neuroblastomas without MYCN amplification, MYCN-amplified neuroblastomas expressed higher levels of EZH2. ChIP analysis showed that MYCN binds at the EZH2 promoter, thereby directly driving expression. Transcriptomic and epigenetic analysis, as well as genetic rescue experiments, revealed that EZH2 represses neuronal differentiation in neuroblastoma in a PRC2-dependent manner. Moreover, MYCN-amplified and high-risk primary tumors from patients with neuroblastoma exhibited strong repression of EZH2-regulated genes. Additionally, overexpression of IGFBP3, a direct EZH2 target, suppressed neuroblastoma growth in vitro and in vivo. We further observed strong synergy between histone deacetylase inhibitors and EZH2 inhibitors. Together, these observations demonstrate that MYCN upregulates EZH2, leading to inactivation of a tumor suppressor program in neuroblastoma, and support testing EZH2 inhibitors in patients with MYCN-amplified neuroblastoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci90793

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

Metadata

Authors
Chen, L., Alexe, G., Dharia, N. V., Ross, L., Iniguez, A. B., Conway, A. S., Wang, E. J., Veschi, V., Lam, N., Qi, J., Gustafson, W. C., Nasholm, N., Vazquez, F., Weir, B. A., Cowley, G. S., Ali, L. D., Pantel, S., Jiang, G., Harrington, W. F., Lee, Y., Goodale, A., Lubonja, R., Krill-Burger, J. M., Meyers, R. M., Tsherniak, A., Root, D. E., Bradner, J. E., Golub, T. R., Roberts, C. W. M., Hahn, W. C., Weiss, W. A., Thiele, C. J., & Stegmaier, K.
Venue
Journal of Clinical Investigation
Published
2017-12-04
Volume
128
Issue
1
Pages
446-462
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2774087343
Cited by
152
References
19
FWCI
7.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.